Table 1.
Patients’ clinicopathologic characteristics.
| Characteristics | All (n = 20, %) |
BRCA Mutation (n = 10, %) |
BRCA Wild-Type (n = 10, %) |
p |
|---|---|---|---|---|
| Age, years | ||||
| Mean ± SD | 52.8 ± 8.4 | 54.2 ± 9.4 | 51.4 ± 7.4 | 0.705 |
| Family Hx of breast cancer | 1 (5.0) | 1 (10.0) | 0 | >0.999 |
| Family Hx of ovarian cancer | 1 (5.0) | 1 (10.0) | 0 | >0.999 |
| FIGO stage | 0.779 | |||
| IIIA | 2 (10.0) | 1 (10.0) | 1 (10.0) | |
| IIIB | 1 (5.0) | 1 (10.0) | 0 | |
| IIIC | 11 (55.0) | 5 (50.0) | 6 (60.0) | |
| IV | 6 (30.0) | 3 (30.0) | 3 (30.0) | |
| CA-125, IU/mL | ||||
| Median (range) | 798.5 (5.1–3545.0) | 798.0 (5.1–3545.0) | 798.5 (47.0–2433.0) | 0.940 |
| Lymph node metastasis | 12 (60.0) | 6 (60.0) | 6 (60.0) | >0.999 |
| Residual tumor after surgery | 0.139 | |||
| No gross | 14 (70.0) | 9 (90.0) | 5 (50.0) | |
| <1 cm | 5 (25.0) | 1 (10.0) | 4 (40.0) | |
| ≥1 and <2 cm | 1 (5.0) | 0 | 1 (10.0) | |
| Chemotherapy at primary treatment | 0.628 | |||
| 6 cycles of paclitaxel–carboplatin | 14 (70.0) | 6 (60.0) | 8 (80.0) | |
| 9 cycles of paclitaxel–carboplatin | 6 (30.0) | 4 (40.0) | 2 (20.0) | |
| Recurrence | 16 (80.0) | 9 (90.0) | 7 (70.0) | 0.582 |
| Treatment-free interval, months | ||||
| Median (range) | 20.4 (3.0–73.0) | 20.9 (13.5–73.0) | 19.6 (3.0–67.9) | 0.496 |
| Germline BRCA1 mutational status | 0.033 | |||
| Wild-type | 15 (75.0) | 5 (50.0) | 10 (100.0) | |
| Mutation | 5 (25.0) | 5 (50.0) | 0 | |
| Germline BRCA2 mutational status | 0.033 | |||
| Wild-type | 15 (75.0) | 5 (50.0) | 10 (100.0) | |
| Mutation | 5 (25.0) | 5 (50.0) | 0 |
Abbreviations: CA-125, cancer antigen 125; FIGO, International Federation of Gynecology and Obstetrics; Hx, history; SD, standard deviation.